---
title: å“Œç”²é…¯
description: 
---

>
> ä¸Šç”Ÿç‰©è¯¾ä¸­ï¼Œè®²åˆ°ç¥ç»è°ƒèŠ‚......
>
> ç”Ÿç‰©è€å¸ˆ(*æ•²é»‘æ¿*)ï¼šè¿™æ˜¯å¯å¡å› ï¼Œä¼šæŠ‘åˆ¶å¤šå·´èƒºè½¬è¿ä½“ï¼Œå¯¼è‡´å¤šå·´èƒºæµ“åº¦å¼‚å¸¸å‡é«˜ï¼Œå±äºæ¯’å“ï¼åŒå­¦ä»¬ççˆ±ç”Ÿå‘½è¿œç¦»æ¯’å“å“ˆ
>
> è¿‡äº†ä¸€ä¼šå„¿ï¼Œ
>
> ç”Ÿç‰©è€å¸ˆ(*è‹¥æœ‰æ‰€æ€*)ï¼šè¿™æ˜¯å“Œç”²é…¯ï¼Œæ˜¯èªæ˜è¯ï¼æ¯•ç«Ÿå°±ç®—ä½ ç†¬å¤œåˆ·é¢˜ï¼Œçªè§¦ä¸å…´å¥‹ä¹Ÿæ²¡æœ‰ç”¨å“ˆã€‚æˆ‘ä»¬åŒ»å­¦ç³»çš„å­¦ç”Ÿï¼Œæ¯é€¢æœŸæœ«è€ƒè¯•ï¼Œç»å¸¸ç»™è‡ªå·±å¼€ä¸€ç“¶å“Œç”²é…¯ç”¨æ¥åˆ·é¢˜ï¼Œå¾ˆç®¡ç”¨ï¼
>


[â—€è¿”å›](./home.md)

# å“Œç”²é…¯

| **å“Œç”²é…¯ (Methylphenidate)** | |
| --- | --- | 
| [![Methylphenidate.png](/æ–‡ä»¶/Methylphenidate.png)](/æ–‡ä»¶/Methylphenidate.png) |
| **åŒ–å­¦å‘½å** |
| å¸¸ç”¨å |  *Methylphenidate, Concerta, Methylin, Ritalin, Equasym XL* |
| å–ä»£åç§° | *å“Œç”²é…¯* |
| ç³»ç»Ÿåç§° | *Methyl 2-phenyl-2-piperidin-2-ylacetate* |
| **ç±»åˆ«å½’å±** |
| ç²¾ç¥æ´»æ€§ç±»åˆ« | *[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)* |
| åŒ–å­¦ç±»åˆ« | *[å“Œå•¶ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md)* |
| **[ç»™è¯é€”å¾„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** |
| **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿæ€§çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»è¾ƒä½å‰‚é‡å¼€å§‹ã€‚ [å¦è§è´Ÿè´£ä»»çš„ç”¨è¯ç« èŠ‚](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚ |
| **[å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** |
| [ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) | |
| [ç”Ÿç‰©åˆ©ç”¨åº¦](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) | 11-52%[\[1\]](#cite_note-Health_Canada_-_Ritalin-1) |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 5 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 10 - 20 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 20 - 40 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 40 - 60 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 60 mg + |
| [è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 2.5 - 4 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 30 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 20 - 45 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 60 - 90 åˆ†é’Ÿ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 45 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 2 - 6 å°æ—¶ |
| **[é¼»å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** |
| [ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) | |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 1 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 2 - 10 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 10 - 30 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 30 - 60 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 60 mg + |
| [è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 2 - 4 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 5 - 20 åˆ†é’Ÿ |
| [è¯æ•ˆä¸Šå‡](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 15 - 40 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 30 - 45 åˆ†é’Ÿ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 2 - 4 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 1 - 4 å°æ—¶ |
| **[å…è´£å£°æ˜](/å…³äºæœ¬ç«™/home.md)ï¼š** æœ¬ç«™çš„ [ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) ä¿¡æ¯æ˜¯ä»ç”¨æˆ·å’Œ [èµ„æº](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md) ä¸­æ”¶é›†çš„ï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚ |
| **[è¯ç‰©è”ç”¨](#å±é™©çš„ç›¸äº’ä½œç”¨)** |
| é…’ç²¾ | âš ï¸ è°¨æ…è”ç”¨ |
| MXE | â›” ä¸¥ç¦è”ç”¨ |
| è§£ç¦»å‰‚ | âš ï¸ è°¨æ…è”ç”¨ |
| DXM | ğŸ’” è”ç”¨å±é™© |
| MDMA | ğŸ’” è”ç”¨å±é™© |
| å…´å¥‹å‰‚ | ğŸ’” è”ç”¨å±é™© |
| 25x-NBOMe | ğŸ’” è”ç”¨å±é™© |
| 25x-NBOH | ğŸ’” è”ç”¨å±é™© |
| æ›²é©¬å¤š | ğŸ’” è”ç”¨å±é™© |
| å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚ | â›” ä¸¥ç¦è”ç”¨ |

**å“Œç”²é…¯**ï¼ˆä¹Ÿå« **MPH**ã€**MPD**ï¼Œå•†å“ååŒ…æ‹¬ **åˆ©ä»–æ—** (Ritalin)ã€**ä¸“æ³¨è¾¾** (Concerta) å’Œ **Methylin** ç­‰ï¼‰æ˜¯å“Œå•¶ç±»çš„ä¸€ç§ç»å…¸å¼ºæ•ˆ [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) ç‰©è´¨å–µã€‚å®ƒæ˜¯ [å–ä»£å“Œå•¶ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md) çš„æ¯ä½“åŒ–åˆç‰©ï¼Œè¿™æ˜¯ä¸€ä¸ªåŒ…æ‹¬ [ä¹™åŸºå“Œç”²é…¯](/è¯ç‰©/EPH.md)ã€[å¼‚ä¸™åŸºå“Œç”²é…¯](/è¯ç‰©/IPPH.md) ç­‰åœ¨å†…çš„å…´å¥‹å‰‚å®¶æ—ã€‚å…¶ä½œç”¨æœºåˆ¶æ¶‰åŠå¢åŠ  [ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨.md) [å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md) å’Œ [å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md) çš„æµ“åº¦å“¦ã€‚

å®ƒäº1944å¹´é¦–æ¬¡åˆæˆï¼Œå¹¶äº1955å¹´åœ¨ç¾å›½è·å‡†ç”¨äºåŒ»ç–—ç”¨é€”ã€‚æœ€åˆç”±ç‘å£«å…¬å¸ CIBAï¼ˆç°ä¸ºè¯ºåï¼‰é”€å”®ã€‚[\[2\]](#cite_note-2) å®ƒè¢«æ‰¹å‡†ç”¨äºæ²»ç–—æ³¨æ„åŠ›ç¼ºé™·å¤šåŠ¨éšœç¢ (ADHD) å’Œå‘ä½œæ€§ç¡ç—…ã€‚æ‚£æœ‰æˆ–ä¸æ‚£æœ‰ ADHD çš„å­¦ç”Ÿç»å¸¸å°†å…¶ç”¨ä½œè®¤çŸ¥å¢å¼ºå‰‚å’Œå­¦ä¹ è¾…åŠ©å‰‚å‘¢ã€‚

[ä¸»è§‚æ•ˆåº”](/è¯æ•ˆ/ä¸»è§‚æ•ˆåº”ç´¢å¼•.md) åŒ…æ‹¬ [åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md)ã€[ä¸“æ³¨åŠ›å¼ºåŒ–](/è¯æ•ˆ/ä¸“æ³¨åŠ›å¼ºåŒ–.md)ã€[åŠ¨æœºå¢å¼º](/è¯æ•ˆ/åŠ¨æœºå¢å¼º.md)ã€[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)ã€[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md) å’Œ [æ¬£å¿«](/è¯æ•ˆ/è®¤çŸ¥æ¬£å¿«.md)ã€‚é€šå¸¸å£æœï¼Œä½†ä¹Ÿå¯ä»¥ [é¼»å¸æˆ–ç›´è‚ ç»™è¯](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)ã€‚å…¶æ•ˆåº”ä¸è‹¯ä¸™èƒºç›¸å½“ï¼›ç„¶è€Œï¼Œæ®æŠ¥é“å®ƒäº§ç”Ÿçš„æ¬£å¿«æ„Ÿè¾ƒå°‘ï¼Œè€Œä¸”é€šå¸¸å¨±ä¹ä»·å€¼è¾ƒä½å–µã€‚ä¸€äº›ç”¨æˆ·è¿˜æŠ¥å‘Šè¯´ï¼Œç›¸å¯¹äºè‹¯ä¸™èƒºï¼Œå®ƒä¼šäº§ç”Ÿæ›´å¼ºçƒˆçš„è¯æ•ˆæ¶ˆé€€æ„Ÿï¼Œå°¤å…¶æ˜¯åœ¨é«˜å‰‚é‡ä¸‹ã€‚

å®ƒå…·æœ‰ä¸­ç­‰çš„æ»¥ç”¨æ½œåŠ›ã€‚é•¿æœŸä½¿ç”¨ï¼ˆå³é«˜å‰‚é‡ã€é‡å¤ç»™è¯ï¼‰ä¸ [å¼ºè¿«æ€§è¡¥é‡](/è¯æ•ˆ/å¼ºè¿«æ€§è¡¥é‡.md)ã€ä¸æ–­å‡çº§çš„è€å—æ€§å’Œå¿ƒç†ä¾èµ–æœ‰å…³ã€‚å¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å– [ä¼¤å®³å‡å°‘](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md) æªæ–½å“¦ã€‚

## ç›®å½•

* [1 å†å²ä¸æ–‡åŒ–](#å†å²ä¸æ–‡åŒ–)
* [2 åŒ–å­¦](#åŒ–å­¦)
    * [2.1 å³æ—‹å“Œç”²é…¯](#å³æ—‹å“Œç”²é…¯)
* [3 è¯ç†å­¦](#è¯ç†å­¦)
* [4 ä¸»è§‚æ•ˆåº”](#ä¸»è§‚æ•ˆåº”)
    * [4.1 **èº«ä½“æ•ˆåº”**](#èº«ä½“æ•ˆåº”)
    * [4.2 **è®¤çŸ¥æ•ˆåº”**](#è®¤çŸ¥æ•ˆåº”)
    * [4.3 **è¯æ•ˆæ®‹ä½™**](#è¯æ•ˆæ®‹ä½™)
    * [4.4 ä½“éªŒæŠ¥å‘Š](#ä½“éªŒæŠ¥å‘Š)
* [5 æ¯’æ€§å’Œå±å®³æ½œåŠ›](#æ¯’æ€§å’Œå±å®³æ½œåŠ›)
    * [5.1 ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›](#ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›)
    * [5.2 ç²¾ç¥ç—…](#ç²¾ç¥ç—…)
    * [5.3 ä¸é…’ç²¾è”ç”¨](#ä¸é…’ç²¾è”ç”¨)
        * [5.3.1 é…’ç²¾è¯±å¯¼çš„å‰‚é‡å€¾æ³» (AIDD)](#é…’ç²¾è¯±å¯¼çš„å‰‚é‡å€¾æ³»_AIDD)
    * [5.4 å±é™©çš„ç›¸äº’ä½œç”¨](#å±é™©çš„ç›¸äº’ä½œç”¨)
* [6 æ³•å¾‹åœ°ä½](#æ³•å¾‹åœ°ä½)
* [7 å¦è§](#å¦è§)
* [8 å¤–éƒ¨é“¾æ¥](#å¤–éƒ¨é“¾æ¥)
* [9 æ–‡çŒ®](#æ–‡çŒ®)
* [10 å‚è€ƒèµ„æ–™](#å‚è€ƒèµ„æ–™)

## å†å²ä¸æ–‡åŒ–

è¯¥åŒ–åˆç‰©äº1944å¹´ç”±åŒ–å­¦å®¶ Leandro Panizzon é¦–æ¬¡åˆæˆï¼Œå¹¶äº1954å¹´ç”±ç‘å£«å…¬å¸ CIBAï¼ˆç°ä¸ºè¯ºåï¼‰ä»¥â€œRitalinâ€ï¼ˆåˆ©ä»–æ—ï¼‰çš„åç§°é”€å”®ã€‚â€œRitalinâ€è¿™ä¸ªåå­—æºäº Panizzon å¦»å­çš„åå­—ï¼Œå³ Margueriteï¼Œæ˜µç§° Ritaï¼Œ[\[3\]](#cite_note-3) å¥¹ä½¿ç”¨åˆ©ä»–æ—æ¥å¼¥è¡¥ä½è¡€å‹å–µã€‚[\[4\]](#cite_note-4)

ç›´åˆ°1954å¹´ï¼Œå“Œç”²é…¯æ‰è¢«æŠ¥é“ä¸ºä¸€ç§å…´å¥‹å‰‚ã€‚[\[5\]](#cite_note-5) è¯¥è¯ç‰©äº1957å¹´åœ¨ç¾å›½å¼•å…¥åŒ»ç–—ç”¨é€”ã€‚[\[6\]](#cite_note-6) è™½ç„¶æœ€åˆç”¨äºç¼“è§£ [å·´æ¯”å¦¥ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±»ç‰©è´¨.md) å¼•èµ·çš„æ˜è¿·ã€å‘ä½œæ€§ç¡ç—…å’ŒæŠ‘éƒç—‡ã€‚[\[7\]](#cite_note-7) åæ¥å®ƒè¢«ç”¨æ¥æ²»ç–—è€å¹´äººçš„è®°å¿†ç¼ºé™·ã€‚[\[8\]](#cite_note-8) éšç€åŒ»å­¦å’Œå¿ƒç†å¥åº·ç•Œå¯¹ ADHD è¯Šæ–­çš„æ›´å¥½ç†è§£å’Œæ›´æ™®éæ¥å—ï¼Œå…¶äº§é‡å’Œå¤„æ–¹é‡ä»…åœ¨1990å¹´ä»£æ˜¾ç€å¢åŠ ï¼Œå°¤å…¶æ˜¯åœ¨ç¾å›½å“¦ã€‚[\[9\]](#cite_note-9)

2000å¹´ï¼ŒAlza Corporation è·å¾—ç¾å›½ FDA æ‰¹å‡†é”€å”® Concertaï¼ˆä¸“æ³¨è¾¾ï¼‰ï¼Œè¿™æ˜¯ä¸€ç§å“Œç”²é…¯çš„ç¼“é‡Šå‰‚å‹ã€‚[\[10\]](#cite_note-10)[\[11\]](#cite_note-11)

æ®ä¼°è®¡ï¼Œ2013å¹´å…¨çƒä½¿ç”¨çš„å“Œç”²é…¯å‰‚é‡æ¯”2012å¹´å¢åŠ äº†66%ã€‚[\[12\]](#cite_note-12) 2022å¹´ï¼Œå®ƒæ˜¯ç¾å›½ç¬¬32å¤§å¸¸ç”¨å¤„æ–¹è¯ï¼Œå¤„æ–¹é‡è¶…è¿‡1700ä¸‡ä»½ã€‚[\[13\]](#cite_note-13) å®ƒå¯ä»¥ä½œä¸ºä»¿åˆ¶è¯è·å¾—å‘¢ã€‚[\[14\]](#cite_note-14)

## åŒ–å­¦

å“Œç”²é…¯æ˜¯ [å–ä»£è‹¯ä¹™èƒº](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯ä¹™èƒºç±»ç‰©è´¨.md) å’Œ [å–ä»£å“Œå•¶](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md) ç±»çš„ä¸€ç§åˆæˆåˆ†å­ã€‚å®ƒåŒ…å«ä¸€ä¸ªè‹¯ä¹™èƒºæ ¸å¿ƒï¼Œå…¶è‹¯ç¯é€šè¿‡ä¹™åŸºé“¾ç»“åˆåˆ°ä¸€ä¸ªæ°¨åŸº (-NH2) ä¸Šã€‚

å®ƒåœ¨ç»“æ„ä¸Šç±»ä¼¼äº [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md)ï¼Œåœ¨å…¶ RÎ± ä½ç½®æœ‰ä¸€ä¸ªå–ä»£åŸºï¼Œè¯¥å–ä»£åŸºè¢«ç»“åˆåˆ°ä¸€ä¸ª [å“Œå•¶](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹„åŸºå“Œå•¶ç±»ç‰©è´¨.md) ç¯ä¸­ï¼Œç»ˆæ­¢äºè‹¯ä¹™èƒºé“¾çš„æœ«ç«¯èƒºã€‚æ­¤å¤–ï¼Œå®ƒçš„ç»“æ„ä¸­åŒ…å«ä¸€ä¸ªç»“åˆåˆ° RÎ² çš„ç”²åŸºç¾§é…¸é…¯ã€‚

### å³å“Œç”²é…¯

å“Œç”²é…¯æ˜¯ä¸€ç§æ‰‹æ€§åŒ–åˆç‰©ï¼Œå¤§æ¦‚æ˜¯ä½œä¸ºå¤–æ¶ˆæ—‹æ··åˆç‰©ç”Ÿäº§çš„ã€‚å®ƒæœ‰ä¸€ç§å¯¹æ˜ çº¯å½¢å¼ä¹Ÿä½œä¸ºè¯ç‰©å‡ºå”®ï¼›å³æ—‹å¯¹æ˜ çº¯å½¢å¼è¢«ç§°ä¸ºâ€œ**å³å“Œç”²é…¯**â€ï¼ˆdexmethylphenidateï¼‰ï¼Œé€šå¸¸ä»¥ **Focalin** å’Œ **Focalin XR** çš„åç§°å‡ºå”®ã€‚

å“Œç”²é…¯å¯èƒ½æœ‰å››ç§å¼‚æ„ä½“ï¼Œå› ä¸ºè¯¥åˆ†å­æœ‰ä¸¤ä¸ªæ‰‹æ€§ä¸­å¿ƒã€‚åŒºåˆ†å‡ºä¸€å¯¹è‹å¼å¼‚æ„ä½“å’Œä¸€å¯¹èµ¤å¼å¼‚æ„ä½“ï¼Œå…¶ä¸­ä¸»è¦æ˜¯ d-è‹å¼-å“Œç”²é…¯è¡¨ç°å‡ºè¯ç†å­¦æ‰€éœ€çš„æ•ˆåº”ã€‚[\[15\]](#cite_note-15)

èµ¤å¼éå¯¹æ˜ å¼‚æ„ä½“æ˜¯ *å‡å‹* èƒºï¼Œè¿™æ˜¯è‹å¼éå¯¹æ˜ å¼‚æ„ä½“æ‰€ä¸å…·å¤‡çš„ç‰¹æ€§ã€‚å½“è¯¥è¯ç‰©é¦–æ¬¡æ¨å‡ºæ—¶ï¼Œå®ƒæ˜¯ä½œä¸ºèµ¤å¼:è‹å¼éå¯¹æ˜ å¼‚æ„ä½“çš„ 4:1 æ··åˆç‰©å‡ºå”®çš„ï¼Œä½†åæ¥è¢«é‡æ–°é…åˆ¶ä¸ºä»…åŒ…å«è‹å¼éå¯¹æ˜ å¼‚æ„ä½“ã€‚â€œTMPâ€æŒ‡çš„æ˜¯ä¸å«ä»»ä½•èµ¤å¼éå¯¹æ˜ å¼‚æ„ä½“çš„è‹å¼äº§å“ï¼Œå³ (Â±)-è‹å¼-å“Œç”²é…¯ã€‚ç”±äºè‹å¼å¼‚æ„ä½“åœ¨èƒ½é‡ä¸Šæ›´æœ‰åˆ©ï¼Œå› æ­¤å¾ˆå®¹æ˜“å·®å‘å¼‚æ„åŒ–æ‰ä»»ä½•ä¸éœ€è¦çš„èµ¤å¼å¼‚æ„ä½“ã€‚

ä»…åŒ…å«å³æ—‹å“Œç”²é…¯çš„è¯ç‰©æœ‰æ—¶è¢«ç§°ä¸º d-TMPï¼Œå°½ç®¡è¿™ä¸ªåç§°å¾ˆå°‘ä½¿ç”¨ï¼Œæ›´å¸¸ç”¨çš„æ˜¯å³æ—‹å“Œç”²é…¯ã€d-MPH æˆ– d-è‹å¼-å“Œç”²é…¯ã€‚å·²ç»å‘è¡¨äº†ä¸€ç¯‡å…³äºå¯¹æ˜ ä½“çº¯ (2*R*,2'*R*)-(+)-*è‹å¼*-å“Œç”²é…¯ç›é…¸ç›åˆæˆçš„ç»¼è¿°å–µã€‚[\[16\]](#cite_note-16)

| [![](https://upload.wikimedia.org/wikipedia/commons/thumb/a/a1/Dexmethylphenidate-2D-skeletal.png/250px-Dexmethylphenidate-2D-skeletal.png)](/æ–‡ä»¶/Dexmethylphenidate-2D-skeletal.png) |
| :---: |
| éª¨æ¶å¼ä¸­çš„å³æ—‹å“Œç”²é…¯ |

## è¯ç†å­¦

å“Œç”²é…¯ä¸»è¦ä½œä¸ºä¸€ç§ [å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md)-[å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md) [å†æ‘„å–æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/ç¥ç»é€’è´¨å†æ‘„å–æŠ‘åˆ¶å‰‚.md) (NDRI) å‘æŒ¥ä½œç”¨ã€‚å®ƒåœ¨è°ƒèŠ‚å¤šå·´èƒºæ°´å¹³æ–¹é¢æœ€æ´»è·ƒï¼Œå…¶æ¬¡æ˜¯å»ç”²è‚¾ä¸Šè…ºç´ ã€‚[\[17\]](#cite_note-17) å“Œç”²é…¯ç»“åˆå¹¶é˜»æ–­å¤šå·´èƒºè½¬è¿ä½“å’Œå»ç”²è‚¾ä¸Šè…ºç´ è½¬è¿ä½“ã€‚[\[18\]](#cite_note-Iversen2006-18)

è™½ç„¶ [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md) å’Œå“Œç”²é…¯éƒ½æ˜¯å¤šå·´èƒºèƒ½è¯ç‰©ï¼Œä½†å€¼å¾—æ³¨æ„çš„æ˜¯å®ƒä»¬çš„ä½œç”¨æ–¹å¼æœ‰äº›ä¸åŒã€‚å…·ä½“æ¥è¯´ï¼Œå“Œç”²é…¯æ˜¯ä¸€ç§å¤šå·´èƒºå†æ‘„å–æŠ‘åˆ¶å‰‚ï¼Œè€Œè‹¯ä¸™èƒºæ—¢æ˜¯ [å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md) å’Œ [å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md) çš„é‡Šæ”¾å‰‚ï¼Œä¹Ÿæ˜¯å®ƒä»¬çš„å†æ‘„å–æŠ‘åˆ¶å‰‚ã€‚æ¯ç§è¯ç‰©å¯¹å»ç”²è‚¾ä¸Šè…ºç´ éƒ½æœ‰ç›¸åº”çš„æ•ˆåº”ï¼Œè¿™æ¯”å®ƒä»¬å¯¹å¤šå·´èƒºçš„æ•ˆåº”è¦å¼±ã€‚

å“Œç”²é…¯åœ¨å¤šå·´èƒº-å»ç”²è‚¾ä¸Šè…ºç´ é‡Šæ”¾æ–¹é¢çš„ä½œç”¨æœºåˆ¶ä»æœ‰äº‰è®®ï¼Œä½†ä¸å¤§å¤šæ•°å…¶ä»–è‹¯ä¹™èƒºè¡ç”Ÿç‰©æ ¹æœ¬ä¸åŒï¼Œå› ä¸ºå“Œç”²é…¯è¢«è®¤ä¸ºä¼šå¢åŠ ä¸€èˆ¬çš„æ”¾ç”µç‡ï¼Œè€Œè‹¯ä¸™èƒºé€šè¿‡æ¿€æ´» TAAR1 é™ä½æ”¾ç”µç‡å¹¶é€†è½¬å•èƒºçš„æµåŠ¨å–µã€‚[\[19\]](#cite_note-19)[\[18\]](#cite_note-Iversen2006-18)[\[20\]](#cite_note-20)[\[21\]](#cite_note-21)

## ä¸»è§‚æ•ˆåº”

***å…è´£å£°æ˜ï¼š** ä¸‹é¢åˆ—å‡ºçš„æ•ˆåº”å¼•ç”¨äº† [***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/è¯æ•ˆ/ä¸»è§‚æ•ˆåº”ç´¢å¼•.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ [PsychonautWiki](/å…³äºæœ¬ç«™/PsychonautWiki.md) è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®å“¦ã€‚å› æ­¤ï¼Œåº”è¯¥å¸¦ç€å¥åº·çš„æ€€ç–‘æ€åº¦æ¥çœ‹å¾…å®ƒä»¬å‘¢ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡é«˜å‰‚é‡æ›´å®¹æ˜“è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚åŒæ ·ï¼Œ**ä¸è‰¯ååº”** éšç€å‰‚é‡çš„å¢åŠ å˜å¾—è¶Šæ¥è¶Šå¯èƒ½å‘ç”Ÿï¼Œå¹¶ä¸”å¯èƒ½åŒ…æ‹¬ **æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **[èº¯ä½“æ•ˆåº”](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md)** ![Child.png](/æ–‡ä»¶/Child.png)
*   **[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md)** - å“Œç”²é…¯é€šå¸¸è¢«æŠ¥é“ä¸ºå…·æœ‰é«˜åº¦çš„èƒ½é‡å’Œç‹¬ç‰¹çš„åˆºæ¿€æ€§ï¼Œç±»ä¼¼äº [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md) æˆ– [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md)ï¼Œå¹¶ä¸”æ¯” [è«è¾¾è²å°¼](/è¯ç‰©/è«è¾¾è²å°¼.md) å’Œ [å’–å•¡å› ](/è¯ç‰©/å’–å•¡å› .md) æ›´å¼ºã€‚åœ¨ä¸­ä½å‰‚é‡ä¸‹ï¼Œå®ƒé¼“åŠ±ä¸€èˆ¬çš„ç”Ÿäº§åŠ›ï¼Œä½†åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒå¯ä»¥é¼“åŠ±ä½“è‚²æ´»åŠ¨ï¼Œå¦‚è·³èˆã€ç¤¾äº¤ã€è·‘æ­¥æˆ–æ¸…æ´ã€‚å“Œç”²é…¯å‘ˆç°çš„ç‰¹å®šåˆºæ¿€é£æ ¼å¯ä»¥æè¿°ä¸ºå¼ºè¿«æ€§çš„ã€‚è¿™æ„å‘³ç€åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œéšç€ä¸‹é¢Œç´§å’¬ã€ä¸è‡ªä¸»çš„èº«ä½“é¢¤æŠ–å’ŒæŒ¯åŠ¨å‡ºç°ï¼Œå˜å¾—éš¾ä»¥æˆ–æ— æ³•ä¿æŒé™æ­¢ï¼Œå¯¼è‡´å…¨èº«å‰§çƒˆé¢¤æŠ–ã€æ‰‹éƒ¨ä¸ç¨³å’Œæ™®éç¼ºä¹è¿åŠ¨æ§åˆ¶ã€‚
*   **[è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰](/è¯æ•ˆ/è‡ªå‘æ€§èº¯ä½“æ„Ÿè§‰.md)**
*   **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)**[\[22\]](#cite_note-Montastruc-22)[\[23\]](#cite_note-Leonard-23)
*   **[å¿ƒå¾‹å¼‚å¸¸](/è¯æ•ˆ/å¿ƒå¾‹å¼‚å¸¸.md)**[\[22\]](#cite_note-Montastruc-22)[\[23\]](#cite_note-Leonard-23)
*   **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md)**
*   **[å°¿é¢‘](/è¯æ•ˆ/å°¿é¢‘.md)**
*   **[å£å¹²](/è¯æ•ˆ/å£å¹².md)**
*   **[é£Ÿæ¬²æŠ‘åˆ¶](/è¯æ•ˆ/é£Ÿæ¬²æŠ‘åˆ¶.md)**[\[23\]](#cite_note-Leonard-23)
*   **[å‡ºæ±—å¢åŠ ](/è¯æ•ˆ/å‡ºæ±—å¢åŠ .md)**
*   **[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md)**[\[23\]](#cite_note-Leonard-23) - å¯èƒ½å‘ç”Ÿåœ¨é«˜å‰‚é‡ä¸‹ï¼Œå°½ç®¡å¾€å¾€ä¼šåœ¨çŸ­æ—¶é—´å†…æ¶ˆé€€ã€‚
*   **[å¤´æ™•](/è¯æ•ˆ/å¤´æ™•.md)**[\[23\]](#cite_note-Leonard-23)
*   **[ç£¨ç‰™](/è¯æ•ˆ/ç£¨ç‰™.md)** - é«˜å‰‚é‡ä¸‹å¯èƒ½ä¼šå‡ºç°ç£¨ç‰™ã€‚ç„¶è€Œï¼Œå®ƒæ¯” [MDMA](/è¯ç‰©/MDMA.md) çš„å¼ºåº¦è¦å°ã€‚
*   **[è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md)** (Vasoconstriction) -> [è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md) (Assuming generic translation/path)
*   **[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)** - é«˜å‰‚é‡çš„å“Œç”²é…¯å¯ä»¥å¢åŠ æ€§æ¬²ã€‚
*   **[ç³å­”æ‰©å¤§](/è¯æ•ˆ/ç³å­”æ‰©å¤§.md)** - è¿™ç§æ•ˆåº”ä»…åœ¨ä¸­ç­‰åˆ°é«˜å‰‚é‡ä»¥åŠä½å…‰ç…§ä¸‹æ‰ä¼šä½“éªŒåˆ°ï¼Œå¹¶ä¸”åœ¨è¯æ•ˆæ¶ˆé€€æœŸæ›´ä¸ºçªå‡ºã€‚

### **[è®¤çŸ¥æ•ˆåº”](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** ![User.png](/æ–‡ä»¶/User.png)

*   **[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md)** - æ®æŠ¥é“ï¼Œç„¦è™‘çš„å‘ç”Ÿé¢‘ç‡ç•¥é«˜äºå…¶ä»–å¸¸è§å…´å¥‹å‰‚ï¼Œå¦‚ [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md) æˆ– [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md)ã€‚
*   **[è®¤çŸ¥æ¬£å¿«](/è¯æ•ˆ/è®¤çŸ¥æ¬£å¿«.md)** - ä¸ [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md) ç­‰å…¶ä»–å¼ºæ•ˆå…´å¥‹å‰‚ç›¸æ¯”ï¼Œå“Œç”²é…¯çš„è®¤çŸ¥æ•ˆåº”é€šå¸¸è¢«ä¸»è§‚æ„ŸçŸ¥ä¸ºæ›´åŠ æ¸…é†’å’Œâ€œåŠŸèƒ½æ€§â€ã€‚
*   **[è‡ªæˆ‘è†¨èƒ€](/è¯æ•ˆ/è‡ªæˆ‘è†¨èƒ€.md)**
*   **[æƒ…æ„ŸæŠ‘åˆ¶](/è¯æ•ˆ/æƒ…æ„ŸæŠ‘åˆ¶.md)** - è¿™é€šå¸¸åœ¨è½»å¾®å’Œä¸­ç­‰å‰‚é‡ä¸‹æœ€å¼ºçƒˆï¼Œå¹¶ä¸”æ›´å¤šåœ°æ¥è‡ªåŒ»ç–—ç”¨é€”è€Œéå¨±ä¹ç”¨é€”çš„æŠ¥å‘Šã€‚
*   **[ç°å®æ„Ÿä¸§å¤±](/è¯æ•ˆ/ç°å®æ„Ÿä¸§å¤±.md)** - è¿™ç§æ•ˆåº”é€šå¸¸åœ¨ä¸­/é«˜å‰‚é‡ä¸‹æŠ¥å‘Šã€‚
*   **[ä¸“æ³¨åŠ›å¼ºåŒ–](/è¯æ•ˆ/ä¸“æ³¨åŠ›å¼ºåŒ–.md)** - è¿™ç§æˆåˆ†åœ¨ä½åˆ°ä¸­ç­‰å‰‚é‡ä¸‹æœ€æœ‰æ•ˆï¼Œå› ä¸ºä»»ä½•æ›´é«˜çš„å‰‚é‡é€šå¸¸éƒ½ä¼šæŸå®³æ³¨æ„åŠ›ã€‚
*   **[æ¸…é†’åº¦](/è¯æ•ˆ/æ¸…é†’åº¦.md)**
*   **[è®°å¿†å¢å¼º](/è¯æ•ˆ/è®°å¿†å¢å¼º.md)** - æ²»ç–—å‰‚é‡çš„å“Œç”²é…¯å¯ä»¥æ”¹å–„æ­£å¸¸åŠŸèƒ½ä¸ªä½“å’Œ ADHD æ‚£è€…åœ¨å·¥ä½œè®°å¿†æµ‹è¯•ä¸­çš„è¡¨ç°ã€‚[\[24\]](#cite_note-24)
*   **[æ—¶é—´æ‰­æ›²](/è¯æ•ˆ/æ—¶é—´æ‰­æ›².md)** - è¿™å¯ä»¥æè¿°ä¸ºä½“éªŒåˆ°æ—¶é—´åŠ é€Ÿå’Œæµé€å¾—æ¯”æ¸…é†’æ—¶å¿«å¾—å¤šçš„æ„Ÿè§‰ã€‚
*   **[æ€ç»´åŠ é€Ÿ](/è¯æ•ˆ/æ€ç»´åŠ é€Ÿ.md)**
*   **[æ€ç»´ç»„ç»‡](/è¯æ•ˆ/æ€ç»´ç»„ç»‡.md)**
*   **[åˆ†æèƒ½åŠ›å¢å¼º](/è¯æ•ˆ/åˆ†æèƒ½åŠ›å¢å¼º.md)**
*   **[åŠ¨æœºå¢å¼º](/è¯æ•ˆ/åŠ¨æœºå¢å¼º.md)**
*   **[æš—ç¤ºæ€§æŠ‘åˆ¶](/è¯æ•ˆ/æš—ç¤ºæ€§æŠ‘åˆ¶.md)**
*   **[éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º](/è¯æ•ˆ/éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º.md)** - ä¸å…¶ä»–å¸¸è§å…´å¥‹å‰‚å¦‚ [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md) æˆ– [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md) ç›¸æ¯”ï¼Œæ®æŠ¥é“è¿™ç§æ•ˆåº”ç›¸å¯¹æ¸©å’Œæˆ–ä»…åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å‡ºç°ã€‚
*   **[å¼ºè¿«æ€§è¡¥é‡](/è¯æ•ˆ/å¼ºè¿«æ€§è¡¥é‡.md)** - æ®æŠ¥é“æœ‰å¼ºè¿«æ€§è¡¥é‡è¡Œä¸ºï¼Œä½†é¢‘ç‡ä½äºå…¶ä»–å¸¸è§å…´å¥‹å‰‚å¦‚ [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md) æˆ– [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md)ï¼Œå¹¶ä¸”é€šå¸¸å‘ç”Ÿåœ¨é‡å‰‚é‡æˆ–éå£æœç»™è¯æ—¶ã€‚

### **è¯æ•ˆæ®‹ä½™** ![Aftereffects_(3).png](/æ–‡ä»¶/Aftereffects_(3).png)

*   [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) ä½“éªŒçš„ [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) æœŸé—´å‘ç”Ÿçš„æ•ˆåº”ï¼Œä¸ [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) æœŸé—´å‘ç”Ÿçš„æ•ˆåº”ç›¸æ¯”ï¼Œé€šå¸¸æ„Ÿè§‰æ˜¯è´Ÿé¢å’Œä¸èˆ’æœçš„ã€‚è¿™é€šå¸¸è¢«ç§°ä¸ºâ€œä¸‹å¤´â€ï¼ˆcomedownï¼‰ï¼Œæ˜¯ç”±äº [ç¥ç»é€’è´¨](/æ–‡æ¡£/ç¥ç»é€’è´¨.md) è€—å°½é€ æˆçš„ã€‚å…¶æ•ˆåº”é€šå¸¸åŒ…æ‹¬ï¼š
* **[ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md)**
* **[è®¤çŸ¥ç–²åŠ³](/è¯æ•ˆ/è®¤çŸ¥ç–²åŠ³.md)**
* **[æŠ‘éƒ](/è¯æ•ˆ/æŠ‘éƒ.md)**
* **[æ˜“æ€’](/è¯æ•ˆ/æ˜“æ€’.md)**
* **[åŠ¨åŠ›æŠ‘åˆ¶](/è¯æ•ˆ/åŠ¨åŠ›æŠ‘åˆ¶.md)**
* **[å¿ƒç‡å¢å¿«](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md)**
* **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/æ€ç»´å‡é€Ÿ.md)**
* **[æ¸…é†’](/è¯æ•ˆ/æ¸…é†’åº¦.md)**
å½“å“Œç”²é…¯ä¸ [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md) å’Œ [å’–å•¡å› ](/è¯ç‰©/å’–å•¡å› .md) ç­‰å…¶ä»–å…´å¥‹å‰‚ç›¸æ¯”æ—¶ï¼Œå®ƒçš„åé—ç—‡æ›´ä¸¥é‡ï¼Œå°±åƒ [MDMA](/è¯ç‰©/MDMA.md) ä¸€æ ·ã€‚

### ä½“éªŒæŠ¥å‘Š

æè¿°è¯¥åŒ–åˆç‰©åœ¨æˆ‘ä»¬ [ä½“éªŒæŠ¥å‘Šç´¢å¼•](/æ–‡æ¡£/æ•™å­¦ç´¢å¼•é¡µ.md) ä¸­çš„æ•ˆåº”çš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

*   [æŠ¥å‘Š/psychounautwiki/Experience: Ritalin 110mg (oral)](/æŠ¥å‘Š/psychounautwiki/Experience:_Ritalin_110mg_(oral).md)
*   [æŠ¥å‘Š/psychounautwiki/Experience:Methylphenidate (45mg, Insufflated) - Phenomenal Focus Aid](/æŠ¥å‘Š/psychounautwiki/Experience:Methylphenidate_(45mg,_Insufflated)_-_Phenomenal_Focus_Aid.md)
*   [æŠ¥å‘Š/psychounautwiki/Experience:Methylphenidate (Insufflated) - Clear Headed Stimulation](/æŠ¥å‘Š/psychounautwiki/Experience:Methylphenidate_(Insufflated)_-_Clear_Headed_Stimulation.md)
*   [æŠ¥å‘Š/psychounautwiki/Experience:Pregabalin (450mg, oral) + Methylphenidate (20mg, oral) - Gaba Flipping](/æŠ¥å‘Š/psychounautwiki/Experience:Pregabalin_(450mg,_oral)_%2B_Methylphenidate_(20mg,_oral)_-_Gaba_Flipping.md)

å¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°æ›´å¤šçš„ä½“éªŒæŠ¥å‘Šï¼š

*   [Erowid Experience Vaults: Methylphenidate](https://www.erowid.org/experiences/subs/exp_Pharms_Methylphenidate.shtml)

## æ¯’æ€§å’Œå±å®³æ½œåŠ›

**è¿™ä¸ªæ¯’æ€§å’Œå±å®³æ½œåŠ›ç« èŠ‚è¿˜æ˜¯ä¸ª[å°è‰ç¨¿](http://psychonautwiki.org/w/index.php?title=Special%3AWhatLinksHere&target=Template%3AStub&namespace=)ã€‚** å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³ **æå…¶é”™è¯¯** çš„ä¿¡æ¯ï¼ä½ å¯ä»¥é€šè¿‡ [æ‰©å……æˆ–æ›´æ­£å®ƒ](https://psychonautwiki.org/w/index.php?title=Methylphenidate&action=edit) æ¥å¸®å¿™å–µã€‚
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶å¹¶ä½¿ç”¨ **[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)**ã€‚*

| [![](https://psychonautwiki.org/w/thumb.php?f=Harmchart.png&width=300)](/æ–‡ä»¶/Harmchart.png) |
| :---: |
| é›·è¾¾å›¾æ˜¾ç¤ºäº†å“Œç”²é…¯ä¸å…¶ä»–è¯ç‰©ç›¸æ¯”çš„ç›¸å¯¹èº«ä½“å±å®³ã€ç¤¾ä¼šå±å®³å’Œä¾èµ–æ€§[\[25\]](#cite_note-25) |

å“Œç”²é…¯çš„ä¸­æ¯’å‰‚é‡è¢«è®¤ä¸ºæ˜¯è¶…è¿‡ 2 mg/kg æˆ– 60 mg çš„é€Ÿé‡Šåˆ¶å‰‚ï¼Œæˆ–è¶…è¿‡ 4 mg/kg æˆ– 120 mg çš„å®Œæ•´ç¼“é‡Šåˆ¶å‰‚ã€‚[\[26\]](#cite_note-26) åœ¨ä¸€é¡¹ç ”ç©¶çš„å¤§å¤šæ•°æ¡ˆä¾‹ä¸­ï¼Œå“Œç”²é…¯è¿‡é‡æ²¡æœ‰ç—‡çŠ¶æˆ–ä»…è¡¨ç°å‡ºè½»å¾®ç—‡çŠ¶ï¼Œå³ä½¿åœ¨ 6 å²ä»¥ä¸‹çš„å„¿ç«¥ä¸­ä¹Ÿæ˜¯å¦‚æ­¤ã€‚

ç„¶è€Œï¼Œç ”ç©¶ä¸­æœ‰ç›¸å½“ä¸€éƒ¨åˆ†æ‚£è€… (31%) å‡ºç°äº†å…¸å‹çš„å…´å¥‹å‰‚è¿‡é‡ç—‡çŠ¶ï¼Œæœ€å¸¸è§çš„æ˜¯å¿ƒåŠ¨è¿‡é€Ÿã€æ¿€è¶Šå’ŒçŸ›ç›¾çš„å—œç¡ã€‚[\[27\]](#cite_note-27) åœ¨ 2012 å¹´å›½å®¶æ¯’ç‰©æ•°æ®ç³»ç»ŸæŠ¥å‘Šä¸­ï¼ŒæŠ¥å‘Šäº† 9,787 æ¬¡å“Œç”²é…¯æš´éœ²ï¼Œå…¶ä¸­ 1,609 æ¬¡æŠ¥å‘Šæ²¡æœ‰ä¸è‰¯ååº”ï¼Œ1,009 æ¬¡æŠ¥å‘Šè½»å¾®ååº”ï¼Œ662 æ¬¡æŠ¥å‘Šä¸­åº¦ååº”ï¼Œ33 æ¬¡æŠ¥å‘Šä¸»è¦ç—‡çŠ¶ï¼Œæ²¡æœ‰å¯¼è‡´æ­»äº¡çš„ç—…ä¾‹ã€‚[\[28\]](#cite_note-28)

å¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å– [ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md) å–µã€‚

### ä¾èµ–å’Œæ»¥ç”¨æ½œåŠ›

å°±å…¶è€å—æ€§è€Œè¨€ï¼Œå“Œç”²é…¯å¯ä»¥è¿ç»­å¤šå¤©é•¿æœŸä½¿ç”¨ï¼Œå¹¶ä¸”ç»å¸¸è¢«å¤„æ–¹ä»¥æ­¤æ–¹å¼ä½¿ç”¨ã€‚é•¿æœŸé‡å¤ä½¿ç”¨ä¼šå¯¹å“Œç”²é…¯çš„è®¸å¤šæ•ˆåº”äº§ç”Ÿè€å—æ€§ã€‚è¿™å¯¼è‡´ä½¿ç”¨è€…å¿…é¡»æœç”¨è¶Šæ¥è¶Šå¤§çš„å‰‚é‡æ‰èƒ½è¾¾åˆ°ç›¸åŒçš„æ•ˆåº”ã€‚[\[29\]](#cite_note-29)

åœ¨æ€¥æ€§ï¼ˆå³ä¸€æ¬¡æ€§ï¼‰æš´éœ²çš„æƒ…å†µä¸‹ï¼Œé€šå¸¸éœ€è¦å¤§çº¦ 3 - 7 å¤©æ‰èƒ½ä½¿è€å—æ€§å‡åŠï¼Œ1 - 2 å‘¨æ‰èƒ½æ¢å¤åˆ°åŸºçº¿ï¼ˆåœ¨æ²¡æœ‰è¿›ä¸€æ­¥æ¶ˆè€—çš„æƒ…å†µä¸‹ï¼‰ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\] å“Œç”²é…¯ä¸æ‰€æœ‰å¤šå·´èƒºèƒ½å…´å¥‹å‰‚éƒ½å­˜åœ¨äº¤å‰è€å—æ€§ï¼Œè¿™æ„å‘³ç€åœ¨æ¶ˆè€—å“Œç”²é…¯åï¼Œæ‰€æœ‰å…´å¥‹å‰‚çš„æ•ˆåº”éƒ½ä¼šé™ä½ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]

ä¸å…¶ä»– [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) ä¸€æ ·ï¼Œé•¿æœŸä½¿ç”¨å“Œç”²é…¯å¯è¢«è§†ä¸ºå…·æœ‰ä¸­åº¦æˆç˜¾æ€§ï¼Œå…·æœ‰å¾ˆé«˜çš„æ»¥ç”¨æ½œåŠ›ï¼Œå¹¶ä¸”èƒ½å¤Ÿå¯¼è‡´æŸäº›ä½¿ç”¨è€…äº§ç”Ÿå¿ƒç†ä¾èµ–ã€‚å½“æˆç˜¾å½¢æˆæ—¶ï¼Œå¦‚æœä¸€ä¸ªäººçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æ¸´æœ›å’Œ [æˆ’æ–­ååº”](/æ–‡æ¡£/è¯ç‰©æˆ’æ–­ååº”.md)ã€‚

ç”±äºå…¶å¯¹å¤šå·´èƒºè½¬è¿ä½“çš„ä½œç”¨ï¼Œå“Œç”²é…¯å…·æœ‰ä¸€å®šçš„æ»¥ç”¨æ½œåŠ›ã€‚åƒå…¶ä»– [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) ä¸€æ ·ï¼Œå“Œç”²é…¯ä¼šå¢åŠ å¤§è„‘ä¸­çš„ [å¤šå·´èƒº](/æ–‡æ¡£/å¤šå·´èƒº.md) æ°´å¹³ã€‚ç„¶è€Œï¼Œåœ¨æ²»ç–—å‰‚é‡ä¸‹ï¼Œè¿™ç§å¢åŠ æ˜¯ç¼“æ…¢çš„ï¼Œå› æ­¤å³ä½¿é™è„‰æ³¨å°„ä¹Ÿå¾ˆå°‘å‡ºç°æ¬£å¿«æ„Ÿã€‚[\[30\]](#cite_note-Volkow1999-30) å› æ­¤ï¼Œå“Œç”²é…¯çš„æ»¥ç”¨å’Œæˆç˜¾æ½œåŠ›æ˜¾ç€ä½äºå…¶ä»–å¤šå·´èƒºèƒ½å…´å¥‹å‰‚ã€‚[\[30\]](#cite_note-Volkow1999-30)[\[31\]](#cite_note-31)

å½“å“Œç”²é…¯è¢«å‹ç¢å¹¶ [é¼»å¸](/æ–‡æ¡£/ç»™è¯é€”å¾„.md) æˆ– [æ³¨å°„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md) æ—¶ï¼Œæ»¥ç”¨æ½œåŠ›ä¼šå¢åŠ ã€‚[\[32\]](#cite_note-Morton2000-32)ã€‚ä½†åº”æ³¨æ„ï¼Œç”±äºè¯ä¸¸ä¸­çš„å¡«å……ç‰©ï¼Œè¿™å¯èƒ½ä¼šæŸå®³é¼»è…”ï¼Œé™è„‰æ³¨å°„ä¼šå¯¼è‡´ [è‚ºæ°”è‚¿](https://en.wikipedia.org/wiki/Emphysema)ï¼ˆä¸€ç§ä¸‹å‘¼å¸é“ç–¾ç—…ï¼Œå½“ç”±åˆ©ä»–æ—ç‰‡å‰‚å¼•èµ·æ—¶ä¹Ÿç§°ä¸º [åˆ©ä»–æ—è‚º](https://en.wikipedia.org/wiki/Emphysema#Ritalin_lung)ï¼‰ã€‚é™è„‰æ³¨å°„å“Œç”²é…¯ï¼ˆé€šå¸¸ä»¥åˆ©ä»–æ—é”€å”®å¹¶å¹¿æ³›ç”¨ä½œæ²»ç–—æ³¨æ„åŠ›ç¼ºé™·å¤šåŠ¨éšœç¢çš„å…´å¥‹å‰‚è¯ç‰©ï¼‰ä¼šå¯¼è‡´ç§°ä¸º [åˆ©ä»–æ—è‚º](https://en.wikipedia.org/wiki/Emphysema#Ritalin_lung) çš„è‚ºæ°”è‚¿æ”¹å˜ã€‚

æ»¥ç”¨å“Œç”²é…¯çš„ä¸»è¦æ¥æºæ˜¯ä»åˆæ³•å¤„æ–¹è½¬ç§»ï¼Œè€Œä¸æ˜¯éæ³•åˆæˆã€‚é‚£äº›å‡ºäºåŒ»ç–—ç›®çš„ä½¿ç”¨å“Œç”²é…¯çš„äººé€šå¸¸æŒ‰æŒ‡ç¤ºå£æœï¼Œè€Œé¼»å†…å’Œé™è„‰æ³¨å°„æ˜¯å¨±ä¹ç”¨é€”çš„é¦–é€‰æ–¹å¼ã€‚[\[33\]](#cite_note-33)

### ç²¾ç¥ç—…

ä¸»æ¡ç›®ï¼š[å…´å¥‹å‰‚ç²¾ç¥ç—…](/æ–‡æ¡£/å…´å¥‹å‰‚ç²¾ç¥ç—….md)

é•¿æœŸä½¿ç”¨ï¼ˆå³é«˜å‰‚é‡ã€é‡å¤ç»™è¯ï¼‰å¯èƒ½ä¼šå¢åŠ  [ç²¾ç¥ç—…](/æ–‡æ¡£/ç²¾ç¥ç—…å‘ä½œ.md) çš„é£é™©ã€‚[\[32\]](#cite_note-Morton2000-32)[\[34\]](#cite_note-34) çŸ­æœŸå“Œç”²é…¯æ²»ç–—çš„å®‰å…¨æ€§å·²ç»ç¡®ç«‹ï¼ŒçŸ­æœŸä¸´åºŠè¯•éªŒæ˜¾ç¤ºåœ¨æ²»ç–—å‰‚é‡æ°´å¹³ä¸‹å“Œç”²é…¯è¯±å‘çš„ç²¾ç¥ç—…å‘ç”Ÿç‡éå¸¸ä½ (0.1%)ã€‚[\[35\]](#cite_note-35)

å“Œç”²é…¯å¼•èµ·çš„ç²¾ç¥ç—…ç—‡çŠ¶å¯èƒ½åŒ…æ‹¬ [å¬å¹»è§‰](/è¯æ•ˆ/å¬è§‰å¹»è§‰.md)ã€[è§†å¹»è§‰](/è¯æ•ˆ/å¤–éƒ¨å¹»è§‰.md)ã€ä¼¤å®³è‡ªå·±çš„å†²åŠ¨ã€ä¸¥é‡çš„ [ç„¦è™‘](/è¯æ•ˆ/ç„¦è™‘.md)ã€[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md)ã€[å»æŠ‘åˆ¶](/è¯æ•ˆ/å»æŠ‘åˆ¶.md)ã€[åæ‰§å’Œå¤¸å¤§å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)ã€[æ··ä¹±](/è¯æ•ˆ/æ··ä¹±.md)ã€[æƒ…æ„ŸæŠ‘åˆ¶](/è¯æ•ˆ/æƒ…æ„ŸæŠ‘åˆ¶.md)ã€æ”»å‡»æ€§å¢åŠ å’Œ [æ˜“æ€’](/è¯æ•ˆ/æ˜“æ€’.md)ã€‚

### ä¸é…’ç²¾è”ç”¨

å“Œç”²é…¯ï¼ˆå£æœæ—¶ï¼‰çš„ç”Ÿç‰©åˆ©ç”¨åº¦è¾ƒä½ï¼Œçº¦ä¸º 30%ã€‚å¦‚æœä¸é…’ç²¾ï¼ˆä¹™é†‡ï¼‰ä¸€èµ·æœç”¨ï¼Œå³æ—‹å“Œç”²é…¯çš„è¡€æµ†æ°´å¹³ä¼šå¢åŠ é«˜è¾¾ 40%ã€‚[\[36\]](#cite_note-36) è¿˜ä¼šå½¢æˆä¸€ç§ç§°ä¸º [ä¹™åŸºå“Œå•¶](/è¯ç‰©/ä¹™åŸºå“Œå•¶.md) çš„ä»£è°¢ç‰©ã€‚[\[37\]](#cite_note-37)

#### é…’ç²¾è¯±å¯¼çš„å‰‚é‡å€¾æ³» (AIDD)

![Skull and crossbones darktextred2.png](/æ–‡ä»¶/Skull_and_crossbones_darktextred2.png)

**å°†é…’ç²¾ä¸ç¼“é‡Šå‰‚å‹è¯ç‰©ç»“åˆä½¿ç”¨å¯èƒ½æ˜¯å±é™©çš„ã€‚**

è¿™ç§å‰‚é‡å€¾æ³»æ•ˆåº”æ˜¯æŒ‡å½“é€šè¿‡ç¼“é‡Šå‰‚å‹ç»™è¯å¹¶åŒæ—¶æ‘„å…¥ä¹™é†‡æ—¶ï¼Œå¤§é‡ç»™å®šè¯ç‰©çš„æ„å¤–å¿«é€Ÿé‡Šæ”¾ã€‚[\[38\]](#cite_note-38) è¿™è¢«è®¤ä¸ºæ˜¯ä¸€ä¸ªè¯å­¦ç¼ºç‚¹ï¼Œå› ä¸ºå®ƒä¼šé€šè¿‡å¢åŠ å¸æ”¶å’Œè¡€æ¸…æµ“åº¦è¶…è¿‡è¯ç‰©çš„æ²»ç–—çª—å£è€Œå¯¼è‡´è¯ç‰©è¯±å¯¼çš„æ¯’æ€§é£é™©å¾ˆé«˜ã€‚é˜²æ­¢è¿™ç§ç›¸äº’ä½œç”¨çš„æœ€ä½³æ–¹æ³•æ˜¯é¿å…åŒæ—¶æ‘„å…¥è¿™ä¸¤ç§ç‰©è´¨ï¼Œæˆ–ä½¿ç”¨ç‰¹å®šçš„æŠ— AIDD æ§é‡Šåˆ¶å‰‚ã€‚

ä½“å¤–æ•°æ®è¡¨æ˜ï¼ŒæŸäº›ç¼“é‡Šå…´å¥‹å‰‚åœ¨é…’ç²¾å­˜åœ¨ä¸‹å¯èƒ½ä¼šç»å†å‰‚é‡å€¾æ³»ã€‚è¿™æ˜¯ä¸€ä¸ªä»¤äººæ‹…å¿§çš„é—®é¢˜ï¼Œå› ä¸º ADHD æ‚£è€…ç¾¤ä½“æœ‰é…—é…’çš„é£é™©ã€‚æœç”¨ç¼“é‡Šå…´å¥‹å‰‚å’Œé…’ç²¾æ—¶å‘ç”Ÿå‰‚é‡å€¾æ³»çš„å¯èƒ½æ€§å¯èƒ½ä¼šç»™ ADHD æ‚£è€…å¸¦æ¥æ„å¤–å’Œå±é™©çš„å‰¯ä½œç”¨ã€‚[\[39\]](#cite_note-39)

ç¼“é‡Šé…æ–¹çš„ä¸€ä¸ªä¾‹å­åŒ…æ‹¬å“Œç”²é…¯è¯ç‰©å“ç‰Œ Concertaï¼ˆä¸“æ³¨è¾¾ï¼‰ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šå•ç‹¬ä½¿ç”¨ç›¸å½“å®‰å…¨çš„ç²¾ç¥æ´»æ€§ç‰©è´¨ï¼Œå½“ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨æä¾›äº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…å«æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com)ã€[DuckDuckGo](https://www.duckduckgo.com)ã€[PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚åˆ—å‡ºçš„ä¸€äº›ç›¸äº’ä½œç”¨æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

*   **[25x-NBOMe](/è¯ç‰©/25I-NBOMe.md) & [25x-NBOH](/è¯ç‰©/25B-NBOH.md)** - 25x åŒ–åˆç‰©å…·æœ‰é«˜åº¦åˆºæ¿€æ€§å’Œèº«ä½“å‹åŠ›ã€‚åº”ä¸¥æ ¼é¿å…ä¸å“Œç”²é…¯è”ç”¨ï¼Œå› ä¸ºå­˜åœ¨è¿‡åº¦ [åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md) å’Œå¿ƒè„å‹åŠ›çš„é£é™©ã€‚è¿™å¯èƒ½å¯¼è‡´ [è¡€å‹å‡é«˜](/è¯æ•ˆ/è¡€å‹å‡é«˜.md)ã€[è¡€ç®¡æ”¶ç¼©](/è¯æ•ˆ/è¡€ç®¡æ”¶ç¼©.md)ã€æƒŠæå‘ä½œã€[æ€ç»´å¾ªç¯](/è¯æ•ˆ/æ€ç»´å¾ªç¯.md)ã€[ç™«ç—«å‘ä½œ](/æ–‡æ¡£/ç™«ç—«å‘ä½œ.md)ï¼Œåœ¨æç«¯æƒ…å†µä¸‹ä¼šå¯¼è‡´å¿ƒåŠ›è¡°ç«­ã€‚
*   **[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)** - å°†é…’ç²¾ä¸ [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) ç»“åˆä½¿ç”¨å¯èƒ½æ˜¯å±é™©çš„ï¼Œå› ä¸ºå­˜åœ¨æ„å¤–è¿‡åº¦ä¸­æ¯’çš„é£é™©ã€‚å…´å¥‹å‰‚ä¼šæ©ç›–é…’ç²¾çš„ [æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) æ•ˆåº”ï¼Œè¿™æ˜¯å¤§å¤šæ•°äººç”¨æ¥è¯„ä¼°å…¶ä¸­æ¯’ç¨‹åº¦çš„æ–¹æ³•ã€‚ä¸€æ—¦å…´å¥‹å‰‚æ¶ˆé€€ï¼Œ[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) æ•ˆåº”å°†ä¸å†å—é˜»ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œä¸¥é‡çš„ [å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚å¦‚æœæ··åˆä½¿ç”¨ï¼Œä½¿ç”¨è€…åº”ä¸¥æ ¼é™åˆ¶è‡ªå·±æ¯å°æ—¶åªå–ä¸€å®šé‡çš„é…’ç²¾ã€‚
*   **[DXM](/è¯ç‰©/å³ç¾æ²™èŠ¬.md)** - åº”é¿å…ä¸ DXM è”ç”¨ï¼Œå› ä¸ºå®ƒå¯¹ [è¡€æ¸…ç´ ](/æ–‡æ¡£/è¡€æ¸…ç´ .md) å’Œ [å»ç”²è‚¾ä¸Šè…ºç´ ](/æ–‡æ¡£/å»ç”²è‚¾ä¸Šè…ºç´ .md) å†æ‘„å–æœ‰æŠ‘åˆ¶ä½œç”¨ã€‚è¿™ä¼šå¢åŠ  [æƒŠæå‘ä½œ](/è¯æ•ˆ/æƒŠæå‘ä½œ.md) å’Œé«˜è¡€å‹å±è±¡çš„é£é™©ï¼Œæˆ–ä¸è¡€æ¸…ç´ é‡Šæ”¾å‰‚ï¼ˆ[MDMA](/è¯ç‰©/MDMA.md)ã€[ç”²åŸºé…®](/è¯ç‰©/ç”²åŸºé…®.md)ã€[ç”²å¡è¥¿é…®](/è¯ç‰©/ç”²å¡è¥¿é…®.md) ç­‰ï¼‰ä¸€èµ·ä½¿ç”¨æ—¶å¢åŠ  [è¡€æ¸…ç´ ç»¼åˆå¾](/æ–‡æ¡£/è¡€æ¸…ç´ ç»¼åˆå¾.md) çš„é£é™©ã€‚ä»”ç»†ç›‘æµ‹è¡€å‹ï¼Œé¿å…å‰§çƒˆçš„ä½“è‚²æ´»åŠ¨ã€‚
*   **[MDMA](/è¯ç‰©/MDMA.md)** - å½“å­˜åœ¨å…¶ä»– [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) æ—¶ï¼ŒMDMA çš„ä»»ä½•ç¥ç»æ¯’æ€§æ•ˆåº”éƒ½å¯èƒ½ä¼šå¢åŠ ã€‚è¿˜å­˜åœ¨è¡€å‹è¿‡é«˜å’Œå¿ƒè„å‹åŠ›ï¼ˆå¿ƒè„æ¯’æ€§ï¼‰çš„é£é™©ã€‚
*   **[MXE](/è¯ç‰©/MXE.md)** - ä¸€äº›æŠ¥å‘Šè¡¨æ˜ï¼Œä¸ MXE è”ç”¨å¯èƒ½ä¼šå±é™©åœ°å¢åŠ è¡€å‹ï¼Œå¹¶å¢åŠ  [èºç‹‚](/è¯æ•ˆ/èºç‹‚.md) å’Œ [ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—…å‘ä½œ.md) çš„é£é™©ã€‚
*   **[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)** - è¿™ä¸¤ç±»è¯ç‰©éƒ½æœ‰ [å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)ã€[èºç‹‚](/è¯æ•ˆ/èºç‹‚.md) å’Œ [ç²¾ç¥ç—…](/è¯æ•ˆ/ç²¾ç¥ç—…å‘ä½œ.md) çš„é£é™©ï¼Œè”ç”¨æ—¶è¿™äº›é£é™©å¯èƒ½ä¼šå€å¢ã€‚
*   **[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)** - å“Œç”²é…¯ä¸ [å¯å¡å› ](/è¯ç‰©/å¯å¡å› .md) ç­‰å…¶ä»– [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) è”ç”¨å¯èƒ½æ˜¯å±é™©çš„ï¼Œå› ä¸ºå®ƒä»¬ä¼šå°† [å¿ƒç‡](/è¯æ•ˆ/å¿ƒç‡å¢å¿«.md) å’Œ [è¡€å‹](/è¯æ•ˆ/è¡€å‹å‡é«˜.md) å¢åŠ åˆ°å±é™©æ°´å¹³ã€‚
*   **[æ›²é©¬å¤š](/è¯ç‰©/æ›²é©¬å¤š.md)** - å·²çŸ¥æ›²é©¬å¤šä¼šé™ä½ç™«ç—«å‘ä½œé˜ˆå€¼[\[40\]](#cite_note-40)ï¼Œä¸å…´å¥‹å‰‚è”ç”¨å¯èƒ½ä¼šè¿›ä¸€æ­¥å¢åŠ è¿™ç§é£é™©ã€‚
*   **[å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/å•èƒºæ°§åŒ–é…¶æŠ‘åˆ¶å‰‚.md)** - è¿™ç§ç»„åˆå¯èƒ½ä¼šå°†å¤šå·´èƒºç­‰ç¥ç»é€’è´¨çš„é‡å¢åŠ åˆ°å±é™©ç”šè‡³è‡´å‘½çš„æ°´å¹³ã€‚ä¾‹å­åŒ…æ‹¬ [éª†é©¼è“¬](/è¯ç‰©/éª†é©¼è“¬.md) (Syrian rue)ã€[*å¡çš®æœ¨*](/è¯ç‰©/æ­»è—¤æ°´.md) (Banisteriopsis caapi) å’Œä¸€äº› [æŠ—æŠ‘éƒè¯](/æ–‡æ¡£/æŠ—æŠ‘éƒè¯.md)ã€‚[\[41\]](#cite_note-41)

## æ³•å¾‹åœ°ä½

åœ¨å›½é™…ä¸Šï¼Œæ ¹æ®ç²¾ç¥è¯ç‰©å…¬çº¦ï¼Œå“Œç”²é…¯æ˜¯é™„è¡¨ II è¯ç‰©ã€‚[\[42\]](#cite_note-42)

*   **æ¾³å¤§åˆ©äºš**ï¼šå“Œç”²é…¯æ˜¯â€œé™„è¡¨ 8â€å—æ§ç‰©è´¨ã€‚æ­¤ç±»è¯ç‰©åœ¨åˆ†å‘å‰å¿…é¡»ä¿å­˜åœ¨å¯é”å®šçš„ä¿é™©ç®±ä¸­ï¼Œæœªç»å¤„æ–¹æŒæœ‰å°†é¢ä¸´å·¨é¢ç½šæ¬¾ç”šè‡³ç›‘ç¦ã€‚[\[43\]](#cite_note-43)
*   **å¥¥åœ°åˆ©**ï¼šæ ¹æ® AMG (Arzneimittelgesetz Ã–sterreich)ï¼Œå“Œç”²é…¯ç”¨äºåŒ»ç–—ç”¨é€”æ˜¯åˆæ³•çš„ï¼Œä½†æ ¹æ® SMG (Suchtmittelgesetz Ã–sterreich)ï¼Œæœªç»å¤„æ–¹é”€å”®æˆ–æŒæœ‰æ˜¯éæ³•çš„ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
*   **åŠ æ‹¿å¤§**ï¼šå“Œç”²é…¯è¢«åˆ—å…¥å—æ§è¯ç‰©å’Œç‰©è´¨æ³•æ¡ˆçš„é™„è¡¨ IIIï¼ˆè¿åŒ LSDã€è‡´å¹»è˜‘è‡å’Œéº¦å¸å¡æ—ï¼‰ã€‚[\[44\]](#cite_note-44) æ ¹æ®é£Ÿå“å’Œè¯ç‰©æ³•æ¡ˆä¸‹çš„é£Ÿå“å’Œè¯ç‰©æ³•è§„ G éƒ¨åˆ†ï¼ˆG.01.002 èŠ‚ï¼‰ï¼Œæœªç»å¤„æ–¹æŒæœ‰æ˜¯éæ³•çš„ã€‚
*   **æ³•å›½**ï¼šå“Œç”²é…¯è¢«åˆ—ä¸ºâ€œstupÃ©fiantâ€ï¼Œå³å…¬è®¤çš„æ»¥ç”¨è¯ç‰©ã€‚å®ƒåªèƒ½åœ¨éº»é†‰å“å¤„æ–¹è¡¨æ ¼ä¸Šå¼€å…·ã€‚[\[45\]](#cite_note-45)
*   **å¾·å›½**ï¼šæ ¹æ® BtMG çš„ Anlage IIIï¼Œå“Œç”²é…¯æ˜¯ä¸€ç§å—æ§ç‰©è´¨ã€‚å®ƒåªèƒ½åœ¨éº»é†‰å“å¤„æ–¹è¡¨æ ¼ä¸Šå¼€å…·ã€‚[\[46\]](#cite_note-46)
*   **æ–°è¥¿å…°**ï¼šå“Œç”²é…¯æ˜¯â€œB2 ç±»å—æ§ç‰©è´¨â€ã€‚éæ³•æŒæœ‰å¯è¢«åˆ¤å¤„å…­ä¸ªæœˆç›‘ç¦ï¼Œåˆ†å‘å¯è¢«åˆ¤å¤„ 14 å¹´ç›‘ç¦ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
*   **ç‘å…¸**ï¼šå“Œç”²é…¯æ˜¯å…·æœ‰å…¬è®¤åŒ»ç–—ä»·å€¼çš„æ¸…å• II å—æ§ç‰©è´¨ã€‚æœªç»å¤„æ–¹æŒæœ‰æœ€é«˜å¯åˆ¤å¤„ä¸‰å¹´ç›‘ç¦ã€‚[\[47\]](#cite_note-47)
*   **ç‘å£«**ï¼šå“Œç”²é…¯æ˜¯ Verzeichnis A ä¸‹ç‰¹åˆ«å‘½åçš„å—æ§ç‰©è´¨ã€‚å…è®¸åŒ»ç–—ç”¨é€”ã€‚[\[48\]](#cite_note-48)
*   **åœŸè€³å…¶**ï¼šå“Œç”²é…¯æ˜¯ä»…é™â€œçº¢è‰²å¤„æ–¹â€çš„ç‰©è´¨[\[49\]](#cite_note-49)ï¼Œæœªç»å¤„æ–¹é”€å”®æˆ–æŒæœ‰æ˜¯éæ³•çš„ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]
*   **è‹±å›½**ï¼šå“Œç”²é…¯æ˜¯å—æ§çš„â€œB ç±»â€ç‰©è´¨ã€‚æœªç»å¤„æ–¹æŒæœ‰å°†è¢«åˆ¤å¤„æœ€é«˜ 5 å¹´ç›‘ç¦å’Œ/æˆ–æ— ä¸Šé™ç½šæ¬¾ï¼Œä¾›åº”å°†è¢«åˆ¤å¤„ 14 å¹´ç›‘ç¦å’Œ/æˆ–æ— ä¸Šé™ç½šæ¬¾ã€‚[\[50\]](#cite_note-50)
*   **ç¾å›½**ï¼šå“Œç”²é…¯è¢«å½’ç±»ä¸ºé™„è¡¨ II å—æ§ç‰©è´¨ï¼Œè¯¥åç§°ç”¨äºå…·æœ‰å…¬è®¤åŒ»ç–—ä»·å€¼ä½†å…·æœ‰é«˜æ»¥ç”¨æ½œåŠ›çš„ç‰©è´¨ã€‚\[*[æ¥æºè¯·æ±‚](/æ–‡æ¡£/æ¥æºè¯·æ±‚.md)*\]

ä¸€ä¸ªæ™®éçš„è¯¯è§£æ˜¯å“Œç”²é…¯å¯èƒ½å¯¼è‡´è¯ç‰©ç­›æŸ¥ä¸­è‹¯ä¸™èƒºçš„å‡é˜³æ€§ã€‚ç„¶è€Œï¼Œå®éªŒå®¤ç ”ç©¶æœªå‘ç°å…ç–«æµ‹å®šäº¤å‰ååº”ã€‚[\[51\]](#cite_note-BreindahlHindersson2012-51)

## å¦è§

*   [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)
*   [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)
*   [è‹¯ä¸™èƒº](/è¯ç‰©/è‹¯ä¸™èƒº.md)

## å¤–éƒ¨é“¾æ¥

*   [Methylphenidate (Wikipedia)](http://en.wikipedia.org/wiki/Methylphenidate)
*   [Methylphenidate (Erowid Vault)](https://www.erowid.org/pharms/methylphenidate/)
*   [Methylphenidate (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=565)
*   [Methylphenidate (DrugBank)](https://go.drugbank.com/drugs/DB00422)
*   [Dexmethylphenidate (DrugBank)](https://go.drugbank.com/drugs/DB06701)
*   [Methylphenidate (Drugs-Forum)](https://drugs-forum.com/wiki/Methylphenidate)

## æ–‡çŒ®

*   Leonard, B. E., McCartan, D., White, J., & King, D. J. (2004). Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Human Psychopharmacology: Clinical and Experimental, 19(3), 151-180. <https://doi.org/10.1002/hup.579>

## å‚è€ƒèµ„æ–™

1. [â†‘](#cite_ref-Health_Canada_-_Ritalin_1-0) "<https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/483/original/Health_Canada_-_Ritalin.PDF?1556050208>"
2. [â†‘](#cite_ref-2) Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., Tucha, O. (December 2010). ["The history of attention deficit hyperactivity disorder"](http://link.springer.com/10.1007/s12402-010-0045-8). *ADHD Attention Deficit and Hyperactivity Disorders*. **2** (4): 241â€“255. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/s12402-010-0045-8](//doi.org/10.1007%2Fs12402-010-0045-8). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1866-6116](//www.worldcat.org/issn/1866-6116).
3. [â†‘](#cite_ref-3) <https://pmc.ncbi.nlm.nih.gov/articles/PMC3000907/#Sec8>
4. [â†‘](#cite_ref-4) Richard L. Myers <https://books.google.com/books?id=a4DuGVwyN6cC&q=named+ritalin+after+his+wife&pg=PA178> ABC-CLIO. p. 178. ISBN 978-0-313-33758-1.
5. [â†‘](#cite_ref-5) Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". *CNS Drugs*. **20** (9): 713â€“738. doi:[10.2165/00023210-200620090-00002](https://link.springer.com/article/10.2165/00023210-200620090-00002). [PMID 16953648.](https://pubmed.ncbi.nlm.nih.gov/16953648/) [S2CID 39535277.](https://www.semanticscholar.org/paper/Methylphenidate-and-its-Isomers-Heal-Pierce/b19872ac87ae24e3cd161a1719d192b9fccffa1b)
6. [â†‘](#cite_ref-6) Wood S, Sage JR, Shuman T, Anagnostaras SG (2014). "Psychostimulants and cognition: A continuum of behavioral and cognitive activation". *Pharmacol Rev*. **66** (1): 193â€“221. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3880463/>
7. [â†‘](#cite_ref-7) Myers RL (August 2007). [*The 100 Most Important Chemical Compounds: A reference guide*.](https://archive.org/details/100mostimportant0000myer) ABC-CLIO. p. 178. [ISBN](/w/index.php?title=ISBN_(identifier)&action=edit&redlink=1 "ISBN (identifier) (page does not exist)") [978-0-313-33758-1](/wiki/Special:BookSources/978-0-313-33758-1 "Special:BookSources/978-0-313-33758-1").
8. [â†‘](#cite_ref-8) Stolerman I (2010). *Encyclopedia of Psychopharmacology*. Berlin, DE / London, UK: Springer. p. 763. ISBN [978-3-540-68698-9](/wiki/Special:BookSources/978-3-540-68698-9 "Special:BookSources/978-3-540-68698-9").
9. [â†‘](#cite_ref-9) Woodworth T (16 May 2000). [DEA Congressional Testimony (Report)](https://web.archive.org/web/20071012061712/http://www.dea.gov/pubs/cngrtest/ct051600.htm). U.S. Drug Enforcement Administration. Archived from [the original](https://www.dea.gov/pubs/cngrtest/ct051600.htm) on 12 October 2007. Retrieved 2 November 2007.
10. [â†‘](#cite_ref-10) ["Concerta- methylphenidate hydrochloride tablet, extended release"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd). *DailyMed*. 1 July 2021.
11. [â†‘](#cite_ref-11) ["Newly Approved Drug Therapies (637) Concerta, Alza".](https://web.archive.org/web/20101216171133/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637) *CenterWatch*. Archived from [the original](https://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637) on 16 December 2010. Retrieved 30 April 2011.
12. [â†‘](#cite_ref-12) ["Narcotics monitoring board reports 66% increase in global consumption of methylphenidate"](http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article). *The Pharmaceutical Journal*. 2015. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1211/PJ.2015.20068042](//doi.org/10.1211%2FPJ.2015.20068042). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [2053-6186](//www.worldcat.org/issn/2053-6186).
13. [â†‘](#cite_ref-13) ["Methylphenidate Drug Usage Statistics, United States, 2013 - 2022"](https://clincalc.com/DrugStats/Drugs/Methylphenidate). *ClinCalc*. Retrieved 30 August 2024.
14. [â†‘](#cite_ref-14) ["Methylphenidate Hydrochloride Monograph for Professionals".](https://www.drugs.com/monograph/methylphenidate.html) *Drugs.com*. AHFS. Archived from [the original](https://web.archive.org/web/20181003194029/https://www.drugs.com/monograph/methylphenidate-hydrochloride.html) on 19 December 2018. Retrieved 19 December 2018.
15. [â†‘](#cite_ref-15) Heal, D. J., Pierce, D. M. (2006). ["Methylphenidate and its Isomers: Their Role in the Treatment of Attention-Deficit Hyperactivity Disorder Using a Transdermal Delivery System"](http://link.springer.com/10.2165/00023210-200620090-00002). *CNS Drugs*. **20** (9): 713â€“738. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2165/00023210-200620090-00002](//doi.org/10.2165%2F00023210-200620090-00002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1172-7047](//www.worldcat.org/issn/1172-7047).
16. [â†‘](#cite_ref-16) Prashad, M. (July 2001). [<379::AID-ADSC379>3.0.CO;2-4 "Approaches to the Preparation of Enantiomerically Pure (2R,2â€²R)-(+)-threo-Methylphenidate Hydrochloride"](https://onlinelibrary.wiley.com/doi/10.1002/1615-4169(200107)343:5). *Advanced Synthesis & Catalysis*. **343** (5): 379â€“392. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/1615-4169(200107)343:5<379::AID-ADSC379>3.0.CO;2-4](//doi.org/10.1002%2F1615-4169%28200107%29343%3A5%3C379%3A%3AAID-ADSC379%3E3.0.CO%3B2-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1615-4150](//www.worldcat.org/issn/1615-4150).
17. [â†‘](#cite_ref-17) Heal, D. J., Pierce, D. M. (1 September 2006). ["Methylphenidate and its Isomers"](https://doi.org/10.2165/00023210-200620090-00002). *CNS Drugs*. **20** (9): 713â€“738. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2165/00023210-200620090-00002](//doi.org/10.2165%2F00023210-200620090-00002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1179-1934](//www.worldcat.org/issn/1179-1934).
18. â†‘ [18.0](#cite_ref-Iversen2006_18-0) [18.1](#cite_ref-Iversen2006_18-1) Iversen, L. (January 2006). ["Neurotransmitter transporters and their impact on the development of psychopharmacology"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1760736/). *British Journal of Pharmacology*. **147** (Suppl 1): S82â€“S88. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1038/sj.bjp.0706428](//doi.org/10.1038%2Fsj.bjp.0706428). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0007-1188](//www.worldcat.org/issn/0007-1188).
19. [â†‘](#cite_ref-19) Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Hitzemann, R., Pappas, N. (October 1998). "Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate". *The American Journal of Psychiatry*. **155** (10): 1325â€“1331. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1176/ajp.155.10.1325](//doi.org/10.1176%2Fajp.155.10.1325). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0002-953X](//www.worldcat.org/issn/0002-953X).
20. [â†‘](#cite_ref-20) Focalin XR review | <http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf>
21. [â†‘](#cite_ref-21) Concerta Xl slow release | <http://www.medicines.org.uk/emc/medicine/8382/SPC/Concerta#PHARMACOLOGICAL_PROPSSPC>
22. â†‘ [22.0](#cite_ref-Montastruc_22-0) [22.1](#cite_ref-Montastruc_22-1) Montastruc, F., Montastruc, G., Montastruc, J.-L., Revet, A. (22 June 2016). ["Cardiovascular safety of methylphenidate should also be considered in adults"](https://www.bmj.com/lookup/doi/10.1136/bmj.i3418). *BMJ*: i3418. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1136/bmj.i3418](//doi.org/10.1136%2Fbmj.i3418). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1756-1833](//www.worldcat.org/issn/1756-1833).
23. â†‘ [23.0](#cite_ref-Leonard_23-0) [23.1](#cite_ref-Leonard_23-1) [23.2](#cite_ref-Leonard_23-2) [23.3](#cite_ref-Leonard_23-3) [23.4](#cite_ref-Leonard_23-4) Leonard, B. E., McCartan, D., White, J., King, D. J. (April 2004). ["Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects"](https://onlinelibrary.wiley.com/doi/10.1002/hup.579). *Human Psychopharmacology: Clinical and Experimental*. **19** (3): 151â€“180. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/hup.579](//doi.org/10.1002%2Fhup.579). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0885-6222](//www.worldcat.org/issn/0885-6222).
24. [â†‘](#cite_ref-24) Nestler, E. J., Hyman, S. E., Malenka, R. C. (2009). *Molecular neuropharmacology: a foundation for clinical neuroscience* (2nd ed ed.). McGraw-Hill Medical. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number) [9780071481274](http://en.wikipedia.org/wiki/Special:BookSources/9780071481274). CS1 maint: Extra text ([link](/w/index.php?title=Category:CS1_maint:_Extra_text&action=edit&redlink=1 "Category:CS1 maint: Extra text (page does not exist)"))
25. [â†‘](#cite_ref-25) Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007). ["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644). *The Lancet*. **369** (9566): 1047â€“1053. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0140-6736](//www.worldcat.org/issn/0140-6736).
26. [â†‘](#cite_ref-26) Scharman, E. J., Erdman, A. R., Cobaugh, D. J., Olson, K. R., Woolf, A. D., Caravati, E. M., Chyka, P. A., Booze, L. L., Manoguerra, A. S., Nelson, L. S., Christianson, G., Troutman, W. G., American Association of Poison Control Centers (November 2007). "Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management". *Clinical Toxicology (Philadelphia, Pa.)*. **45** (7): 737â€“752. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1080/15563650701665175](//doi.org/10.1080%2F15563650701665175). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1556-3650](//www.worldcat.org/issn/1556-3650).
27. [â†‘](#cite_ref-27) White, S. R., Yadao, C. M. (1 December 2000). ["Characterization of Methylphenidate Exposures Reported to a Regional Poison Control Center"](http://archpedi.jamanetwork.com/article.aspx?doi=10.1001/archpedi.154.12.1199). *Archives of Pediatrics & Adolescent Medicine*. **154** (12): 1199. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1001/archpedi.154.12.1199](//doi.org/10.1001%2Farchpedi.154.12.1199). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1072-4710](//www.worldcat.org/issn/1072-4710).
28. [â†‘](#cite_ref-28) 2012 Annual Report of the American Association
of Poison Control Centers â€™ National Poison
Data System (NPDS): 28th Annual Report | <https://aapcc.s3.amazonaws.com/pdfs/annual_reports/2012_NPDS_Annual_Report.pdf>
29. [â†‘](#cite_ref-29) Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., Wigal, S. (September 1999). "Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children". *Clinical Pharmacology and Therapeutics*. **66** (3): 295â€“305. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0009-9236(99)70038-X](//doi.org/10.1016%2FS0009-9236%2899%2970038-X). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0009-9236](//www.worldcat.org/issn/0009-9236).
30. â†‘ [30.0](#cite_ref-Volkow1999_30-0) [30.1](#cite_ref-Volkow1999_30-1) Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., Dewey, S. L., Hitzemann, R., Gifford, A. N., Pappas, N. R. (January 1999). "Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high"". *The Journal of Pharmacology and Experimental Therapeutics*. **288** (1): 14â€“20. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0022-3565](//www.worldcat.org/issn/0022-3565).
31. [â†‘](#cite_ref-31) Volkow, N. D., Swanson, J. M. (November 2003). ["Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD"](https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.160.11.1909). *American Journal of Psychiatry*. **160** (11): 1909â€“1918. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1176/appi.ajp.160.11.1909](//doi.org/10.1176%2Fappi.ajp.160.11.1909). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0002-953X](//www.worldcat.org/issn/0002-953X).
32. â†‘ [32.0](#cite_ref-Morton2000_32-0) [32.1](#cite_ref-Morton2000_32-1) Morton, W. A., Stockton, G. G. (October 2000). ["Methylphenidate Abuse and Psychiatric Side Effects"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181133/). *Primary Care Companion to The Journal of Clinical Psychiatry*. **2** (5): 159â€“164. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1523-5998](//www.worldcat.org/issn/1523-5998).
33. [â†‘](#cite_ref-33) Klein-Schwartz, W. (April 2002). ["Abuse and toxicity of methylphenidate:"](http://journals.lww.com/00008480-200204000-00013). *Current Opinion in Pediatrics*. **14** (2): 219â€“223. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1097/00008480-200204000-00013](//doi.org/10.1097%2F00008480-200204000-00013). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1040-8703](//www.worldcat.org/issn/1040-8703).
34. [â†‘](#cite_ref-34) Spensley, J., Rockwell, D. A. (20 April 1972). ["Psychosis during Methylphenidate Abuse"](https://doi.org/10.1056/NEJM197204202861607). *New England Journal of Medicine*. **286** (16): 880â€“881. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1056/NEJM197204202861607](//doi.org/10.1056%2FNEJM197204202861607). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0028-4793](//www.worldcat.org/issn/0028-4793).
35. [â†‘](#cite_ref-35) Ritalin & Ritalin-SR Prescribing Information | <http://www.pharma.us.novartis.com/product/pi/pdf/ritalin_ritalin-sr.pdf>
36. [â†‘](#cite_ref-36) Patrick, K., Straughn, A., Minhinnett, R., Yeatts, S., Herrin, A., DeVane, C., Malcolm, R., Janis, G., Markowitz, J. (March 2007). ["Influence of Ethanol and Gender on Methylphenidate Pharmacokinetics and Pharmacodynamics"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188424/). *Clinical pharmacology and therapeutics*. **81** (3): 346â€“353. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1038/sj.clpt.6100082](//doi.org/10.1038%2Fsj.clpt.6100082). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0009-9236](//www.worldcat.org/issn/0009-9236).
37. [â†‘](#cite_ref-37) Markowitz, J. S., DeVane, C. L., Boulton, D. W., Nahas, Z., Risch, S. C., Diamond, F., Patrick, K. S. (June 2000). "Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol". *Drug Metabolism and Disposition: The Biological Fate of Chemicals*. **28** (6): 620â€“624. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0090-9556](//www.worldcat.org/issn/0090-9556).
38. [â†‘](#cite_ref-38) D'Souza S, Mayock S, Salt A (December 2017). "A review of in vivo and in vitro aspects of alcohol-induced dose dumping". *AAPS Open* (in English). **3** (1). [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1186/s41120-017-0014-9](//doi.org/10.1186%2Fs41120-017-0014-9)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.png/langen-gb-20px-Lock-green.png.png "Freely accessible"). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [2364-9534](//www.worldcat.org/issn/2364-9534).
39. [â†‘](#cite_ref-39) Jain, R; Stark, JG (September 2016). "Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications". *Postgraduate medicine*. **128** (7): 672â€“81. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1080/00325481.2016.1218259](//doi.org/10.1080%2F00325481.2016.1218259). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier) [27467139](//www.ncbi.nlm.nih.gov/pubmed/27467139).
40. [â†‘](#cite_ref-40) Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". *Journal of Medical Toxicology*. **5** (2): 63â€“67. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1007/BF03161089](//doi.org/10.1007%2FBF03161089). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN) [1937-6995](//www.worldcat.org/issn/1937-6995). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [1556-9039](//www.worldcat.org/issn/1556-9039). [OCLC](http://en.wikipedia.org/wiki/OCLC) [163567183](//www.worldcat.org/oclc/163567183).
41. [â†‘](#cite_ref-41) Gillman, P. K. (2005). ["Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity"](https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext). *British Journal of Anaesthesia*. **95** (4): 434â€“441. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/bja/aei210](//doi.org/10.1093%2Fbja%2Faei210)â€¯![Freely accessible](https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.png/langen-gb-20px-Lock-green.png.png "Freely accessible"). [eISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number#Electronic_ISSN) [1471-6771](//www.worldcat.org/issn/1471-6771). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0007-0912](//www.worldcat.org/issn/0007-0912). [OCLC](http://en.wikipedia.org/wiki/OCLC) [01537271](//www.worldcat.org/oclc/01537271). [PMID](http://en.wikipedia.org/wiki/PubMed_Identifier) [16051647](//www.ncbi.nlm.nih.gov/pubmed/16051647).
42. [â†‘](#cite_ref-42) "Green List: Annex to the annual statistical report on psychotropic substances (form P)" (PDF). Archived from the original (PDF) on 31 August 2012. (1.63 MB) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Retrieved 2 March 2006.
43. [â†‘](#cite_ref-43) ["POISONS STANDARD DECEMBER 2019"](https://www.legislation.gov.au/Details/F2019L01471). Office of Parliamentary Counsel. Retrieved December 24, 2019.
44. [â†‘](#cite_ref-44) ["SCHEDULE III"](https://web.archive.org/web/20110416090043/http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28). Department of Justice. Archived from [the original](http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-32.html#h-28) on April 16, 2011. Retrieved December 24, 2019.
45. [â†‘](#cite_ref-45) [*ArrÃªtÃ© du 22 fÃ©vrier 1990 fixant la liste des substances classÃ©es comme stupÃ©fiants*](https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/)
46. [â†‘](#cite_ref-46) [*Anlage III BtMG - Einzelnorm*](http://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html)
47. [â†‘](#cite_ref-47) [*Narkotikastrafflag (1968:64) (NSL), Lagen.nu*](https://lagen.nu/1968:64)
48. [â†‘](#cite_ref-48) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
49. [â†‘](#cite_ref-49) <https://www.titck.gov.tr/dinamikmodul/43>
50. [â†‘](#cite_ref-50) [*Misuse of Drugs Act 1971*](https://www.legislation.gov.uk/ukpga/1971/38/schedule/2)
51. [â†‘](#cite_ref-BreindahlHindersson2012_51-0) Breindahl, Torben; Hindersson, Peter (2012). "Methylphenidate is Distinguished from Amphetamine in Drug-of-Abuse Testing". *Journal of Analytical Toxicology*. **36** (7): 538â€“539. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1093/jat/bks056](//doi.org/10.1093%2Fjat%2Fbks056). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number) [0146-4760](//www.worldcat.org/issn/0146-4760).